52 signals · alpha_vantage, bluesky, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Elevated risk signals — operational or reputational pressure patterns observed.
Signal data from 1 source places BioNTech in the Biotechnology / mRNA space at moderate workforce stress signals with elevated risk indicators.
Signals for BioNTech were collected from 1 source. Aggregate signal sentiment appears broadly cautionary. The stress score stands at 60/100 with a risk score of 91/100. Signal coverage is sufficient to support a preliminary assessment.
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly…
Berenberg Raises Price Target on BioNTech to $140 From $132, Keeps Buy Rating marketscreener.com
Immunotherapy company using mRNA technology.
Based on 52 signals across 3 sources · snapshot 18 Sept 2026
Strong — enough signals from diverse sources to trust this score.
Overall community sentiment for BioNTech is negative based on public signals as of 18 Sept 2026.
Based on 52 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
What this means
Moderate internal stress paired with elevated risk signals — conditions bear watching.
AI-generated from public signals — may be incomplete. Based on 3 recent signals.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
AI summaries are generated from public signals and may not reflect the full picture.
BioNTech price target raised to $140 from $132 at Berenberg TipRanks